

# RIBER

Press release – Revenues at the end of September 2010

Bezons, October 14th, 2010; 5:45 pm

## **Revenues at end of September 2010: €7.6 million Order book: €19.1 million (+155% compared with September 30th, 2009)**

*Bezons, October 14th, 2010 – 5:45 pm – RIBER, the global leader for molecular beam epitaxy (MBE), is publishing its revenues at the end of September 2010. With strong growth in its order book, RIBER is forecasting over €19 million in revenues for the full year, combined with an improvement in its earnings.*

At September 30th (€'000,000)	2010	2009	Change
Systems	2.8	5.2	-46%
Services and accessories	4.2	2.6	+60%
Cells and sources	0.6	1.7	-61%
<b>Total reported revenues</b>	<b>7.6</b>	<b>9.5</b>	<b>-20%</b>
Systems order book	12.4	4.8	+158%
Services and accessories order book	2.7	2.0	+35%
Cells and sources order book	4.0	0.7	x4.7
<b>Total order book</b>	<b>19.1</b>	<b>7.5</b>	<b>+155%</b>

At September 30th, 2010, RIBER's consolidated revenues totaled €7.6 million, compared with €9.5 million one year earlier. Revenues for the third quarter of 2010 came to €3.2 million, versus €3.6 million for the third quarter of 2009.

MBE system sales represented €2.8 million at September 30th, 2010, compared with €5.2 million at September 30th, 2009. It is important to note that a €2.5 million production system has been produced, but will only be delivered in December for contractual reasons.

The contraction in sales of evaporation sources and cells is to be put into perspective, with a delivery schedule that is concentrated over the final quarter of the year.

The services and accessories business is on track for strong growth, with sales climbing 60% compared with September 30th, 2009.

### **Revenue and earnings growth target confirmed for 2010**

The order book is up 155% in relation to September 30th, 2009, representing €19.1 million, generated by 10 MBE systems, with two production systems and eight research systems (including three systems to be delivered in 2011). It also factors in major effusion cell orders intended for the strongly growing OLED (Organic LED) and thin-layer solar panels (CIGS technology) sectors.

All combined, this dynamic commercial development confirms the relevance of RIBER's business model, based on:

- Continuing to further strengthen RIBER's leadership on the market for MBE research and production systems;

- Capitalizing on the installed base and growing sales of epitaxy equipment, spare parts and accessories, as well as the corresponding services;
- Releasing a range of high value-added equipment and services on the market for strong-growth application fields (thin-layer solar panels, OLED lighting and flat screens, etc.).

In view of the delivery schedule for the end of the year, RIBER is expected to record over €19 million in revenues for 2010, paving the way for a further improvement in profitability.

**2010 annual revenues will be released on Thursday January 13th, 2011 (after close of trading).**

**About RIBER:**

Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-technology equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, such as new information technologies, OLED lighting and flat screens, as well as new generation solar panels.

Riber is listed on Euronext Paris Compartment "C" and is part of the CAC IT index.

ISIN: FR0000075954 Reuters code: RIBE.PA Bloomberg code: RIB: FP

Riber has been innovation certified by OSEO, the dedicated French innovation agency, enabling it to qualify for French innovation mutual funds (FCPI).

**Your contacts:**

**RIBER**

Olivier Handschumacher  
tel: +33 1 39 96 65 00  
ohandschumacher@riber.fr

**CALYPTUS**

Cyril Combe  
tel: +33 1 53 65 68 68  
cyril.combe@calyptus.net

**[www.riber.com](http://www.riber.com)**